𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of Open-Label, 8-Week Trials of Olanzapine Monotherapy and Topiramate Augmentation of Olanzapine for the Treatment of Pediatric Bipolar Disorder

✍ Scribed by Wozniak, Janet; Mick, Eric; Waxmonsky, James; Kotarski, Meghan; Hantsoo, Liisa; Biederman, Joseph

Book ID
126592962
Publisher
Mary Ann Liebert
Year
2009
Tongue
English
Weight
205 KB
Volume
19
Category
Article
ISSN
1044-5463

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Olanzapine monotherapy for acute depress
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial
✍ William V. Bobo; Richard A. Epstein; Richard C. Shelton πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

## Abstract We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open‐label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery–Asb

Safety and efficacy of olanzapine monoth
Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study
✍ Jun Chen; David J. Muzina; David E. Kemp; Carla Conroy; Philip Chan; Mary Beth S πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 190 KB

## Objective To examine the safety and efficacy of olanzapine monotherapy in treatment‐resistant bipolar mania. ## Method Subjects (__n__ = 18) who were acutely manic, did not respond to lithium, anticonvulsants, and neuroleptics, and/or had intolerable side effects to them in previous manic epis